Abstract
ents were CMVMM. CMVMM patients surviving 30 days were excluded (n 2). Results: Group 1(n 19) received IV ganciclovir 5mg/kg 3x week for 10 weeks. Group 2(n 7) received IV ganciclovir 5mg/kg BD for 14 days then IV ganciclovir 5mg/kg or oral ganciclovir at 1gm TDS 3x week for a further 10 weeks plus IV CMVIG @ 3x10units on days 1,2,3,7,14,28,56,84. Ref: CMV and Rejection Status Table Conclusion: Prophylatic CMV-IG resulted in a significant reduction in the incidence of rejection within the first 6 months post LTx. However it did not reduce the development of initial CMV disease. Further followup is required to determine long term outcomes, especially recurrence of CMV disease and prevalence of BOS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
